{
    "clinical_study": {
        "@rank": "119470", 
        "arm_group": {
            "arm_group_label": "Icotinib and arsenic trioxide", 
            "arm_group_type": "Experimental", 
            "description": "Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.\nArsenic trioxide is administered by intravenous injection with an initial dose of  4mg/m2 per day for day 1 to day 14 every 28 days.\nThree dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
        }, 
        "brief_summary": {
            "textblock": "The NSCLC patients who experienced good clinical responses to an EGFR-TKI will inevitably\n      develop acquired resistance. A great deal of research are focusing on this issue.  Arsenic\n      trioxide showed efficacy and safety in acute promyelocytic leukemia, multiple myeloma and\n      other solid tumors. Moreover, preclinical studies showed arsenic trioxide can reduce the\n      resistance of tumor cells to chemotherapy and TKIs."
        }, 
        "brief_title": "Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to Icotinib", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed stage IIIB/IV lung cancer with EGFR\n             mutation (19/21)\n\n          -  Progressed after platinum-based chemotherapy\n\n          -  The last anti-tumor therapy before entering this study must be icotinib, and the\n             duration for tumor response must be no less than 4 months, or the duration for stable\n             disease must be no less than 6 months\n\n          -  With a measurable disease with conventional CT) according to RECIST Criteria\n\n          -  WHO performance status(PS)<= 2\n\n          -  N>=1.5\u00d7109/L, Plt>=1.0\u00d7109/L,Hb>=9g/dL; AST&ALT should <2.5ULN(without liver\n             metastasis) or <5ULN(with liver metastasis).TBIL<=1.5ULN.\n\n          -  Signed and dated informed consent before the start of specific protocol procedures.\n\n        Exclusion Criteria:\n\n          -  Allergic to icotinib or arsenic trioxide.\n\n          -  Patients with metastatic brain tumors with symptoms.\n\n          -  Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or\n             small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab.\n\n          -  Severe systemic disease out of control such as unstable or uncompensated\n             respiratory,cardiac,liver,renal diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066870", 
            "org_study_id": "BD-IC-IV55"
        }, 
        "intervention": [
            {
                "arm_group_label": "Icotinib and arsenic trioxide", 
                "description": "Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.", 
                "intervention_name": "Icotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BPI-9000", 
                    "Commana"
                ]
            }, 
            {
                "arm_group_label": "Icotinib and arsenic trioxide", 
                "description": "Arsenic trioxide is administered by intravenous injection with an initial dose of  4mg/m2 per day for day 1 to day 14 every 28 days.\nThree dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved.", 
                "intervention_name": "Arsenic trioxide", 
                "intervention_type": "Drug", 
                "other_name": "Arsenic trioxide for injection"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Arsenic trioxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Icotinib", 
            "Arsenic Trioxide", 
            "Resistance", 
            "Non-small cell lung cancer"
        ], 
        "lastchanged_date": "April 20, 2014", 
        "location": {
            "contact": {
                "last_name": "Yuankai Shi, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College"
            }, 
            "investigator": {
                "last_name": "Yuankai Shi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of the Combination of Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to Icotinib", 
        "overall_contact": {
            "last_name": "Yuankai Shi, MD", 
            "phone": "0086-13701251865"
        }, 
        "overall_official": [
            {
                "affiliation": "Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine", 
                "last_name": "Saijuan Chen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College", 
                "last_name": "Yuankai Shi, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 months"
            }, 
            {
                "measure": "Time to death", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}